Eight years since going public, creating five "selves" again—what did WuXi AppTec do right?

Ask AI · How does the CRDMO model help WuXi AppTec achieve beyond-expected growth?

This article source: Times Finance Author: Li Yao

In 2018, WuXi AppTec (603259.SH; 02359.HK) was listed on A-shares, with revenue still below 10 billion yuan. At that time, the global pharmaceutical outsourcing industry was on the eve of a golden period of development. With its “integrated, end-to-end” CRDMO model, WuXi AppTec was the first among domestic peers to build a complete closed loop from drug discovery to commercial manufacturing.

In 2025, as the industry moved from broad-based growth toward differentiation and consolidation, WuXi AppTec delivered a performance that exceeded market expectations. The latest disclosed financial report shows that in 2025, WuXi AppTec’s total operating revenue reached 45.46 billion yuan. Revenue from continuing operations increased by 21.4% year-on-year. Net profit attributable to shareholders of the listed company was 19.15 billion yuan, up 102.6%. Adjusted Non-IFRS net profit attributable to the parent was 14.96 billion yuan, up 41.3%.

What has drawn even more attention is that WuXi AppTec’s orders in hand for continuing operations reached 58.0 billion yuan, up 28.8%, locking in a considerable degree of certainty for future growth. On this basis, WuXi AppTec expects that in 2026, the company’s total revenue will reach 51.3 billion to 53.0 billion yuan, with revenue from continuing operations increasing by 18% to 22% year-on-year. At the same time, adjusted free cash flow will reach 10.5 billion to 11.5 billion yuan.

From revenue below 10 billion yuan to over 45 billion yuan, WuXi AppTec achieved a leap in just eight years. What exactly has this company done right? In a world full of uncertainty, can its growth logic be sustained?

Victory of the CRDMO model

WuXi AppTec’s core competitiveness lies in its “integrated, end-to-end” CRDMO business model. This seemingly simple model, in practice, builds a complete closed loop from drug discovery to commercial manufacturing. The front-end research business ® plays the role of a “funnel entrance,” while the back-end development and manufacturing (D&M) is responsible for amplifying the value effect.

The financial report shows that in 2025, WuXi AppTec successfully synthesized and delivered more than 420,000 new chemical compounds for clients. Put another way, the company needed to complete the synthesis and delivery of more than 1,150 new molecules every day. These early-stage projects are not only sources of revenue, but more importantly, they continue to attract business downstream. In 2025, the company transformed 310 molecules from the research stage to the development and manufacturing stage.

This “front-end lead-in, back-end conversion” effect is especially evident in the client structure. As WuXi AppTec disclosed, in 2024 alone, the R-end early-stage business contributed more than 70% of new customers, with 35% of them having successful financing records in the past 5 years. This also means that the R&D capabilities and pipeline quality of this segment have been validated by the capital markets.

WuXi AppTec’s businesses are mainly divided into chemical business (WuXi Chemistry), testing business (WuXi Testing), and biology business (WuXiBiology). As the company’s core growth engine, the chemical business achieved revenue of 36.47 billion yuan in 2025, up 25.5%. Among them, small-molecule D&M business revenue was 19.92 billion yuan, up 11.4%. The financial report points out that in 2025, the small-molecule CDMO pipeline continued to expand, with a total of 839 newly added molecules over the entire year.

In addition, the TIDES business (oligonucleotides and peptides) performed particularly strongly. Full-year revenue reached 11.37 billion yuan, up 96.0%, nearly doubling. By the end of 2025, TIDES orders in hand grew 20.2% year-on-year. The number of D&M service clients increased 25% year-on-year, and the number of service molecules increased 45% year-on-year. In September 2025, WuXi AppTec completed the peptide production capacity construction in Taixing ahead of schedule. The overall volume of the peptide solid-phase synthesis reactors had been increased to over 100,000 liters.

For the CXO industry, the speed of capacity expansion itself is an important competitive advantage. Besides the peptide solid-phase synthesis reactors with a total volume of over 100,000 liters, WuXi AppTec also has GLP labs with an area of more than 120,000 square meters worldwide. In addition, the overall volume of small-molecule active pharmaceutical ingredient (API) reactors exceeds 4,000,000 liters.

And these capacities are not just numbers. In 2025, the Changzhou, Taixing, and Jinshan API bases all passed on-site inspections by the U.S. Food and Drug Administration (FDA) with “zero defects.” In the pharmaceutical outsourcing industry, there are only a handful of companies that can achieve such a level of quality control.

For pharmaceutical companies, capacity determines the speed of R&D and supply, while quality means projects can be advanced more steadily and listing risks are lower. Both are the most core competitive advantages of CXO companies.

Image source: TuChong

Head effect is gradually emerging

In recent years, the investment and financing environment for biopharmaceuticals has cooled. The industry has moved away from broad-based growth, toward differentiation and consolidation. Against this backdrop, WuXi AppTec’s performance precisely reflects its true capabilities.

From a macro perspective, the innovation-driven engine behind the pharmaceutical industry has always existed. A report by Frost & Sullivan shows that in 2024, global R&D spending reached 277.6 billion US dollars, nearly 10 times the approximately 26 billion US dollars at the time WuXi AppTec was founded in 2000. It is expected to further rise to 476.1 billion US dollars by 2030. The continued growth of global pharmaceutical R&D spending will undoubtedly provide long-term development momentum for the CXO industry.

Meanwhile, patent cliffs force multinational pharmaceutical companies to maintain R&D vitality, but the difficulty and cost of new drug development keep rising. According to Deloitte’s latest report, the average cost for the world’s top pharma companies to successfully bring a new drug to market increased from 1.188 billion US dollars in 2010 to 2.284 billion US dollars in 2022. The rapid surge in R&D spending makes pharma companies’ need for cost reduction and efficiency improvement, as well as risk control, even more urgent—further highlighting the value of the CXO model.

In addition, about 1,000 small biopharmaceutical companies are established worldwide every year. They focus more on how to utilize funds efficiently and push their R&D pipelines as quickly as possible, and they are also more inclined to use contract R&D and manufacturing services. According to Frost & Sullivan’s statistics, in 2024 the penetration rate of pharmaceutical outsourcing rose to over 50%, and it is expected to reach over 65% by 2034.

Under tighter financing conditions, resources are accelerating toward leading high-quality projects and top-tier CXO companies. Small and mid-sized Biotech firms face greater funding pressure, and tend to concentrate limited funds on high-quality projects in the later stages. As a result, top CXO companies—with comprehensive capabilities and excellent delivery quality—benefit more from the optimization of industry structure.

WuXi AppTec’s customer structure in 2025 also confirms the above trend. The financial report shows that during the reporting period, revenue from WuXi AppTec’s U.S. clients reached 31.25 billion yuan, up 34.3%, and accounted for as much as 72% of total revenue contribution—far exceeding the company’s overall growth rate. Even as geopolitical uncertainties intensify, the U.S. market not only contributed the vast majority of revenue, but also maintained strong growth. This in turn reflects WuXi AppTec’s irreplaceability in core technologies, delivery capabilities, and compliance standards.

Creating incremental value and enabling global growth

In the pharmaceutical outsourcing industry, most companies are stuck in a stock game of “winning orders—cutting prices—declining profit margins.” WuXi AppTec has taken a different path: by proactively laying out new tracks, it creates new market demand.

The explosive growth of the TIDES business is the most typical example. As mentioned earlier, in 2025, this segment’s revenue reached 11.37 billion yuan, up 96.0%. Such success is not accidental. It is understood that WuXi AppTec began laying out peptide research and testing capabilities as early as 2011, when peptides were still a niche track. In 2018, WuXi AppTec officially integrated and launched the WuXi TIDES business segment, providing “end-to-end” CRDMO services for oligonucleotides, peptides, and related chemical conjugates. When the industry generally believed that peptide drug production has high barriers and scarce capacity, WuXi AppTec had already prepared capacity, and precisely released it when demand for GLP-1 was strongest.

At the same time, WuXi AppTec’s global expansion is also accelerating, and its service capabilities have already covered major global innovation markets for pharmaceuticals. The financial report shows that in 2025, revenue from U.S. customers was 31.25 billion yuan, up 34.3%. Revenue from European customers was 4.82 billion yuan, down 4% year-on-year. Revenue from Chinese customers was 5.47 billion yuan, down 3.5% year-on-year. Revenue from customers in Japan, South Korea, and other regions was 1.88 billion yuan, up 4.1%. Although some markets experienced volatility, overall, WuXi AppTec’s service network has already developed risk-resistance capabilities across geographies and cycles.

In terms of shareholder returns, WuXi AppTec has also demonstrated strong cash flow generation capability. In 2025, the company proposed total cash dividends of more than 6.7 billion yuan for 2025, setting a new historical high. And it will continue the practice of interim dividends in 2026.

When the industry is looking for direction amid differentiation, WuXi AppTec uses its performance to show that the true moat is not built by chasing trends, but by constructing a system capable of capturing any trend. This may be the fundamental answer to how WuXi AppTec survives through cycles and continues to grow.